A Study in Subjects With Retinitis Pigmentosa

Completed · Phase 2

Conditions studied: Retinitis Pigmentosa

In brief

An open-label Phase II clinical trial, 8 (eight) subjects with retinitis pigmentosa due to rhodopsin mutations (including P23H) will be identified and treated with serial intravitreal injections of ADX-2191 in the worse seeing eye. Ocular structure and function will be evaluated.

Key facts

Study ID

NCT05392179

Run by

Aldeyra Therapeutics, Inc.

People needed

8

Starts

2022-07-14

Expected to finish

2023-06-23

Last updated by the study team

2026-04-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Up to 8 adult patients age 18 or older
• Diagnosis of retinitis pigmentosa due to rhodopsin gene mutation, including P23H
• Impairment on Visual Field as determined by perimetry

You may not qualify if…

• Age < 18 years
• Pregnant
• Previous inflammatory/infectious events involving the eyes

Where it is running

• Duke Eye Center — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.